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examination and the immunohistochemical detection of 
general neuroendocrine markers, such as chromogranin 
A (CgA) and synaptophysin. Serum markers and the use 
of functional imaging techniques are important additive 
tools to establish the diagnosis of a NET. The only cura-
tive option for lung NETs is complete surgical resection. 
Beyond that, the currently available interdisciplinary 
therapeutic options are local ablation, biotherapy (soma-
tostatin analogues), or chemotherapy. New therapeutic 
options such as peptide receptor radionuclide therapy 
(PRRT) and molecularly targeted therapies achieve 
promising results and are under further evaluation. This 
report is a consensus summary of the interdisciplinary 
symposium ‘Neuroendocrine Tumors of the Lung and of 
the Gastroenteropancreatic System (GEP NET) – Expert 
Dialogue’ held on February 25–26, 2011 in Weimar, Ger-
many. At this conference, a panel of 23 German experts 
shared their knowledge and exchanged their thoughts 
about research, diagnosis, and clinical management of 
NETs, whereby special attention was paid to NETs of the 
respiratory tract.
Keywords
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Summary
Neuroendocrine tumors (NETs; syn. carcinoid tumors) 
are highly or moderately differentiated neoplasms. They 
comprise a large variety of rare and heterogeneous 
 tumors with an estimated incidence of 3–5/100,000/year. 
They can arise in virtually every internal organ, but 
mainly occur in the gastroenteropancreatic and bron-
chopulmonary systems. Around 25% of the NETs are 
 localized in the bronchopulmonary system. Approxi-
mately 2% of all lung tumors are NETs. According to the 
World Health Organization (WHO) classification of lung 
tumors, bronchopulmonary NETs are subdivided into 
typical carcinoids (TCs) and atypical carcinoids (ACs). 
The parameter with the highest impact on NET behavior 
and prognosis is the histological classification and stag-
ing according to the tumor/node/metastasis (TNM) sys-
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miological and clinical data on bronchopulmonary NETs in 
Germany is still insufficient.
The registered number of patients with lung NETs has 
been increasing worldwide. Different reasons for this can be 
suspected, such as an improved awareness in the medical 
 community, progress in the accuracy of diagnostic procedures 
in pathology and radiological imaging, as well as recently 
 developed classification systems. Around 25% of all NETs 
originate from the bronchopulmonary system. 20–25% of all 
 malignant lung tumors are neuroendocrine neoplasms 
(NENs), if the poorly differentiated variants are included.
Following the World Health Organization (WHO) classifi-
cation (tables 1 and 2), 80–90% of all carcinoids of the lung 
can be classified as typical carcinoids (TCs), 10–20% as atypi-
cal carcinoids (ACs). 5–15% of the bronchopulmonary carci-
noid tumors are associated with the multiple endocrine neo-
plasia type 1 (MEN-1) syndrome [7]. TCs are defined as well-
differentiated, slowly proliferating tumors with a generally 
good prognosis. ACs are defined as well-differentiated tumors 
with higher mitotic activity than TCs and/or the presence of 
necrosis. Concerning histopathology and prognosis, ACs are 
intermediate between TCs on the one hand and poorly differ-
entiated neuroendocrine carcinomas (NECs), i.e. large-cell 
NEC (LCNEC) and small-cell lung carcinoma (SCLC), on the 
other hand. NECs are highly malignant and have a poor prog-
nosis [5]. The proportion of ACs versus TCs is greater in men 
than in women [8]. In the series from Berlin-Buch, 86 patients 
with carcinoids of the lung had a median age of 63 years at 
initial diagnosis. Thus, carcinoids of the lung appear at the 
same age as lung NECs. However, carcinoids occur more 
often than NECs at a low disease stage. 6 (7%) of the above-
mentioned 86 patients developed secondary tumors mostly 
localized in the lung. However, it remains difficult in these 
Introduction
The term neuroendocrine tumor (NET) refers to a very 
heterogeneous group of highly or moderately differentiated 
tumors characterized by their capacity to accumulate and se-
crete peptide hormones or biogenic amines according to their 
cell of origin. It comprises a huge variety of possible primary 
tumor localizations, with the lung and different organs of the 
gastrointestinal (GI) tract being mostly involved. The classifi-
cation of NETs is based on:
– histology
– proliferative activity
–  tumor/node/metastasis (TNM) staging
– endocrine activity
– hereditary background
Exact classification of NETs is crucial for risk stratification 
and therapeutical management [1–5].
Epidemiology, Classification, and Prognosis
Based on overall 35,618 NET cases that have been included 
into the huge US American Surveillance, Epidemiology and 
End Results (SEER) database from 1973 to 2004, the overall 
incidence of NETs accounts for 3–5 per 100,000 per year, and 
the estimated 29-year limited-duration prevalence is 35 per 
100,000 [6]. Accordingly, the number of new NET cases in 
Germany can be estimated within a range between 1,600 and 
4,000 per year. So far, the German Registry for Gastrointesti-
nal Neuroendocrine Tumors (Deutsches Register Neuroen-
dokrine Gastrointestinale Tumore) has included a large series 
of more than 2,000 patients, but less than 50 patients with 
bronchopulmonary NETs. Therefore, the collection of epide-









Typical carcinoid (TC) yes
Atypical carcinoid (AC) yes
Salivary gland tumors
Preinvasive lesions
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
(DIPNECH)
yes
Table 2. Classification of lung NETs according to WHO 2004 [9]
Tumor type Mitotic counta Necrosis Cell size
Typical carcinoid < 2 absence –
Atypical carcinoid  2–10 absence or punctiform –
Large-cell, poorly differentiated > 10 large larger
Small-cell, poorly differentiated >10 large < 3 lymphocytes
aPer high-power field (2 mm2).





















   
   
   
   
   
   
   
   
   
   
   

























cases to distinguish between metastases or a secondary pri-
mary tumor.
Another rare entity with high differentiation and a very 
low tendency of proliferation and metastasis are neuro-
endocrine tumorlets. They are characterized as multifocally 
distributed TC tumors with a diameter of ≤ 5 mm. This disease 
is  denoted as diffuse idiopathic pulmonary neuroendocrine 
cell hyperplasia (DIPNECH) by the WHO classification. 
DIPNECH is a preneoplastic condition characterized by a 
generalized proliferation of pulmonary neuroendocrine cells 
[4, 9].
In contrast to the digestive tract, poorly differentiated 
NECs predominate in the lung. For example, SCLCs account 
for 15–20% and LCNECs for 3% of all lung tumors. Highly to 
moderately differentiated bronchopulmonary NETs (syn. 
 carcinoids) are rare and comprise approximately 2% of all 
lung tumors [7]. In a series of the Cancer Center Erfurt com-
prising tissue samples of 1,385 resected lung cancer patients, 
70 (5%) tumors were identified as NENs, namely 42 (3%) as 
carcinoids, 24 (1.7%) as LCNECs, and 4 (0.3%) as SCLCs 
with neuroendocrine characteristics [10]. The relatively small 
proportion of SCLCs in this series of resected tissue samples 
from lung cancer patients, which does not correspond to the 
actual prevalence of this tumor type, can be explained by the 
fact that most SCLC patients cannot be treated by surgical 
 resection of the tumor.
A Norwegian registry including 26,665 lung cancers re-
vealed a proportion of 1% carcinoids [11], and the German 
Registry of the Cancer Center Berlin-Buch found a propor-
tion of 1.3% carcinoids in more than 6,000 lung cancers [8]. 
However, data from registries should be interpreted cau-
tiously since there are a variety of limitations, due to diverging 
classification systems and potential allocation bias.
More than 60% of all patients with lung carcinoids are 
 female. The 5-year survival rate in bronchopulmonary carci-
noids is estimated at 90%, in nodal stage N0 at 100% [12]. 
 According to a survival analysis of 200 patients with broncho-
pulmonary NENs, the 5- and 10-year survival rates are 87% 
and 87% for TCs, 56% and 35% for ACs, 27% and 9% for 
LCNECs, and 9% and 5% for SCLCs, respectively [13]. In the 
Berlin-Buch series, the 5-year survival rate was 88% for TCs 
and 71% for ACs [8].
Due to the high proportion of low malignant tumor types 
with a relatively low mortality and long disease duration, the 
prevalence of lung NETs is considerable and can be estimated 
at approximately 5,000 patients in Germany. Nevertheless, in 
comparison with gastroenteropancreatic (GEP) NETs, much 
less data is available to define standards in diagnosis-guided 
and stage-adjusted therapy of lung NETs. The diagnostic and 
therapeutic management of NET patients essentially requires 
an interdisciplinary approach including experts of pathology, 
endocrinology, medical oncology, pulmonology, surgery, radi-
ology, and nuclear medicine.
Clinical Features, Bronchoscopic Exploration,  
and Biopsy
Of all bronchopulmonary carcinoids, 20–30% are localized 
in the periphery of the lung and therefore are mostly asymp-
tomatic. If the tumor is located in the central airways, the 
symptom triad of cough, hemoptysis, and frequent infections 
may be typical of early diagnosis. Only 2% of all patients with 
lung NETs present with the full carcinoid syndrome [7], which 
is caused by an excessive serotonin production and secretion 
by the tumor cells. In contrast to GEP NETs, it is not limited 
to patients with metastatic disease, because serotonin can 
enter the systemic circulation directly via bronchial arteries 
and pulmonal veins.
The parameter with the highest impact on NET behavior 
and prognosis is the histological classification of the tumor. 
Therefore, it is crucial to perform a highly qualified patho-
histological analysis and diagnosis of the tumor. This can only 
be based on a specimen containing enough tumor cells and 
therefore requires at least a needle aspiration biopsy via bron-
choscopy in all cases not eligible for tumor resection accord-
ing to bronchoscopical and radiological findings. Beyond 
 exploration of the primary tumor, endobronchial ultrasound 
with real-time guided transbronchial needle aspiration 
(EBUS-TBNA) allows the reliable diagnosis of mediastinal 
lymph nodes. As an important method of tumor staging, this 
method may replace mediastinoscopy.
The macroscopical features of TCs and ACs are very 
 characteristic, so that a tentative diagnosis can be already 
drawn from bronchoscopical inspection. Carcinoids appear as 
smooth, well-demarcated, grey to yellow lumps (fig. 1). Due to 
their high vascularization, severe bleeding can be induced eas-
ily during biopsy. This can be avoided by the use of adequate 
Fig. 1. (a–c) Carcinoids visualized via broncho-
scopy. Narrow band imaging was used in (b). 
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clinically relevant serum marker for poorly differentiated car-
cinomas (SCLC and LCLC), is not recommended for routine 
pathology, due to its low specificity.
Several other neuropeptides and amines are also fre-
quently found in lung neuroendocrine neoplasms: bombesin, 
calcitonin, adrenocorticotropic hormone (ACTH), Leu- 
enkephalin, gastrin, somatostatin, vasoactive intestinal poly-
peptide (VIP), neurotensin, arginine vasopressin, and sero-
tonin. They may be helpful in identifying the neuroendocrine 
nature of a bronchopulmonary tumor; however, their routine 
pathological examination is not obligatory.
In a functionally active NET, the tumor excessively secretes 
one of a number of peptides or amines, such as 5-hydroxytryp-
tophane, eventually causing specific clinical symptoms, such as 
the carcinoid syndrome due to the excessive secretion of sero-
tonin (see above) or Cushing’s syndrome due to the excessive 
secretion of ACTH.
Transcription factors can be helpful as immunohistochemi-
cal markers to differentiate between lung primaries and lung 
metastases from other tumor entities. For example, thyroid 
transcription factor-1 (TTF-1) is a highly specific indicator of 
a lung primary and, analogically, caudal-related homeobox-2 
(CDX-2)-positive tumors have a high probability to stem 
from the digestive tract.
Circulating Tumor Markers
Measurements of serum or plasma tumor markers can be a 
valuable complementary tool for the follow-up of NET diag-
nostics. However, the levels of circulating biomarkers can 
 fluctuate significantly and, in addition, neuroendocrine mark-
ers can also occur in a variety of non-NET entities. Therefore, 
the primary diagnosis of a NET can never be based on only 
these markers without taking into account other diagnostic 
parameters. In functionally active NETs, the respective pep-
tides or amines produced by the tumor can generally be used 
as diagnostic markers.
Whereas CgA and NSE can be used as valuable tools for 
follow-up examination, they are not suitable for tumor screen-
ing. A third marker frequently used in NET diagnostics is 
5-hydroxyindoleacetic acid (5-HIAA) measured in urine 
 collected for 24 h. As a surrogate parameter of serotonin 
 metabolism, elevated 5-HIAA levels are indicative of a carci-
noid syndrome (see above). Accordingly, 5-HIAA is fre-
quently increased in patients with midgut NETs, but rarely in 
patients with lung NETs. 5-HIAA has a high specificity; how-
ever, many different foods and medications can alter the uri-
nary 5-HIAA levels and may thereby generate false-positive 
results [16, 17]. A further limitation to the sensitivity of 
5-HIAA measurements in lung NETs is given by the fact that 
5-hydroxytryptophane decarboxylase expression is dimin-
ished in many of these tumors, resulting in reduced produc-
tion of 5-HIAA.
prevention measures. Rigid bronchoscopy upon intubation 
anesthesia enables a better control of bleeding complications 
as compared to flexible bronchoscopy and permits obtaining 
big specimens for histological evaluation, either by rigid for-
ceps or cryobiopsy. Therefore, rigid bronchoscopy should be 
preferred as soon as a NET is suspected.
In contrast to needle aspiration biopsy, exfoliative, abra-
sive, or imprinting techniques of cell sampling are insufficient 
for an accurate pathohistological differentiation. In addition, 
it is indispensable for the clinician to supply the pathologist 
with a complementing report including patient characteris-
tics, clinical signs and symptoms, tumor localization and 
dissemination.
Pathohistological Diagnosis
Accordance between the different NEN classification sys-
tems of the WHO, the European Neuroendocrine Tumor Soci-
ety (ENETS), the North American Neuroendocrine Tumor 
Society (NANETS), and the Union for International Cancer 
Control (UICC) has been increasing [1–5, 9, 14]. Standard 
 parameters for the histological differentiation between TCs 
and ACs are the mitotic count and/or the presence of necrosis. 
TCs are characterized by less than 2 mitoses per 2 mm2 and 
the absence of necrosis. Accordingly, carcinoids presenting 
with 2–10 mitoses per 2 mm2 or foci of necrosis are classified 
as ACs [13]. Although not included in the WHO classification, 
Ki-67 can also be useful, at least as an ancillary parameter, for 
the differentiation between TCs and ACs. However, until now 
there is no consensus regarding the Ki-67 cutoff value in order 
to distinguish TCs from ACs. Mitosis rates and Ki-67 values 
differ to a greater extent in lung NETs than in GEP NETs. 
Therefore, it might be helpful to combine both parameters, 
particularly when the histopathological diagnosis remains 
undefined.
In squamous-cell carcinomas or adenocarcinomas, partial 
neuroendocrine differentiation can often be detected; how-
ever, this observation seems to be without any impact on 
prognosis or, according to current knowledge, on the response 
to therapy. These tumors are collectively referred to as 
NSCLCs with partial neuroendocrine differentiation. Never-
theless, the histopathological distinction between non-NEC, 
such as adenocarcinoma, and NEC is crucial in order to 
 understand the biological background of the tumor. Gener-
ally, this discrimination cannot be based on the morphology of 
the tumor cells alone. Hence, for the detection of neuroendo-
crine components, immunohistochemical markers are an es-
sential tool. NSCLC with suggestive neuroendocrine mor-
phology, for example, should be assessed with neuroendocrine 
markers such as CD56, chromogranin A (CgA), and synapto-
physin, which can be indicative of an LCNEC [15]. Virtually 
all TCs and ACs are positive for CgA and/or synaptophysin by 




















   
   
   
   
   
   
   
   
   
   
   

























for more rapid image acquisition at submillimeter slice thick-
ness by 64-row detectors and higher. In imaging with intra-
venous contrast media, it should be taken into account that, 
in general, the vascularization of NETs is extraordinarily 
high. In many cases, tumors can be seen clearly demarcated 
against solid tissues only in a very early (arterial) phase of 
contrast imaging, and therefore fast image acquisition is 
crucial.
According to the European Society for Medical Oncology 
(ESMO) guidelines, after primary surgery of a TC or AC, the 
patient should be followed up by CT or MRI once a year. 
 Patients with metastatic or recurrent disease should be fol-
lowed up more often during treatment with cytotoxic or bio-
logical agents, at 3-month intervals [7].
Another area of great progress during the last decade is 
functional imaging of NETs with the help of molecularly 
 targeted agents. Labeling of somatostatin analogues (SSAs) 
Imaging
In the last decades, imaging technology has remarkably 
 improved and a number of new diagnostic tools have been 
 developed, in NETs and in other tumor entities. In parallel, 
there is a significant increase in image resolution and an 
 improvement of specific contrast techniques. Requirements 
for radiological diagnostics of lung NENs are generally based 
on the same principles as in non-neuroendocrine lung tumors. 
The most important techniques in conventional imaging are 
computed tomography (CT) and magnetic resonance imaging 
(MRI). However, there are some significant advantages of 
using multislice CT in lung diagnostics, such as fast image 
 acquisition to avoid movement artifacts and higher spatial 
resolution facilitating multiplanar reconstruction. For the 
 diagnostics of lung NETs, an at least 16-slice CT is strongly 
recommended, whereas new scanners are usually equipped 
Fig. 2. 68Ga-DOTANOC PET/CT images from 
a 69-year-old patient with an NEC of the right 
 middle lobe of the lung (stage IV) and hepatic 
and mediastinal metastases. Initially, a plati-
num-based chemotherapy was performed, fol-
lowed by treatments with interferon, lantreo-
tide, octreotide, and finally by chemotherapy 
with STZ and doxorubicin. The NEC disease 
progressed during all of these treatments. The 
68Ga-DOTANOC PET/CT shows a primary 
tumor, which is located in segment 6 of the 
right lung and highly positive for SMS-R 
(standardized uptake value (SUV) 18.1) and 
extended bilobular metastases. (a) PET maxi-
mum intensity projection, (b) PET/CT coronal 
section, (c) CT axial section, (d) PET/CT axial 
section. Due to the high SMS-R density of the 
 metastases, PRRT was indicated and per-
formed with very good results, i.e. PR and long 
survival of the patient were achieved. Pictures 
provided by R. P. Baum, Bad-Berka.
Fig. 3. In a 56-year-old female patient with AC 
in the right lobe of the lung, 18F-FDG PET/CT 
images show intensive glucose hypermetabo-
lism (SUV 16.7) of the 7.5-cm-large tumor 
which is obstructing the upper bronchial lobe. 
(a) Maximum intensity projection, (b) PET 
axial section, (c) CT axial section, (d) PET/CT 
axial section, (e–g) coronal sections. The loca-
tions of FDG- positive lymph node metastases 
are right-sided postclavicular, parathyroideal, 
and infracranial. 68Ga-DOTATATE PET/CT 
(h, maximum intensity projection) revealed no 
significant SMS-R expression. Therefore, 
PRRT was not recommended. Pictures pro-
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PET/CT should be generally performed for continuous fol-
low-up diagnostics. An alternative proposal is to use conven-
tional imaging for regular follow-up and, as recommended for 
GEP NETs, to perform a PET/CT every 18–24 months.
TCs tend to be SSTR positive whereas many ACs are 
 better detectable by 18F-fluorodeoxyglucose (18F-FDG) PET/
CT than by using other tracers. Hence, tracer selection should 
be based primarily on the histological classification including 
the proliferation rate of the tumor. If the Ki-67 index exceeds 
10–20%, an FDG-PET/CT is always suitable. In order to iden-
tify the peptide that is best fitting for SMS-R imaging in a 
 particular patient, differentiation of SMS-R subtypes 1–5 
(SSTR1–5) by immunohistochemistry might be considered; 
however, this method is so far not well established. Finally, the 
expression analysis of various subtypes of SMS-Rs in correla-
tion with functional imaging has to be evaluated in further 
studies [19, 20].
Surgical Therapy
The only curative treatment of lung NETs is their complete 
resection. In the Erfurt series [10], the 5-year survival proba-
bility reached 80% in all patients after lung NET resection. 
Even in the subgroup of patients with disease stage IV, a prior 
R0 resection seemed to improve the survival probability 
 compared to patients with lower incomplete resection types. 
However, these observations are preliminary due to method-
ological limitations. Anyway, based on a larger amount of 
data, it has been proven that NET patients after curative 
 surgery have a much better prognosis than patients with carci-
noma of the lung. In the above-mentioned analysis of the Nor-
wegian registry [11], e.g., the 5-year survival rate was 96% 
after resection of TCs and 79% after resection of ACs.
In peripherally localized TCs without suspected node in-
volvement, a parenchyma-sparing resection is indicated, such 
as an ample wedge excision or a segmental resection [21]. 
Bronchial carcinoids are treated by sleeve resection with lo-
bectomy rather than pneumonectomy. In selected cases, iso-
lated bronchial resections and bronchoplastic reconstructions 
without lung resection can be performed [22]. With regard to 
the high frequency of lymphatic involvement in ACs, in most 
cases this tumor type should be treated like bronchial carci-
noma, by radical resection [23].
Centrally located TCs or ACs frequently may cause consid-
erable airway occlusions and are therefore usually discovered 
at an early disease stage. Under certain circumstances, these 
tumors can be resected by the use of minimally invasive tech-
niques. For tumors that are not considered to be surgically 
 resectable, the use of local ablation methods such as cryoabla-
tion or laser ablation can be discussed on an individual basis. 
Interventional bronchoscopy can also be used to restore free 
passage of the respiratory tract. In some cases, this may facili-
tate a later curative surgical approach.
with radioisotopes such as the positron-emitting 68gallium 
 allows the detection of NET primaries and metastases by 
 positron emission tomography (PET)/CT, frequently even if 
they are too small to be detected with conventional imaging 
methods, such as tumors located in the bronchus. PET/CT has 
the highest specificity and sensitivity among the functional im-
aging techniques, followed by single photon emission com-
puted tomography (SPECT)/CT and SPECT and planar so-
matostatin receptor scintigraphy (SRS) [18]. SRS with 111in-
dium has no sufficient sensitivity with regard to the detection 
of lung NETs. Instead, 99mTc SRS is recommended and SRS 
should  always be combined with SPECT.
Beyond highly sensitive tumor detection, functional imag-
ing allows reliable judgment on the somatostatin receptor 
(SMS-R) status of the tumor, including an estimation of the 
receptor density, providing important information concerning 
the suitability of SSAs and peptide receptor radionuclide ther-
apy (PRRT) in the respective patient (figs. 2–4). Immunohisto-
chemical evaluation of the SMS-R subtype 2A (SSTR2A) may 
be helpful as an additive tool, especially in case of initial diag-
nosis of a bronchopulmonary NET. An open question is 
whether in TCs, based on the Response Evaluation Criteria in 
Solid Tumors (RECIST) and the Positron Emission Tomogra-
phy Response Criteria in Solid Tumors (PERCIST), an SMS-R 
Fig. 4. 68Ga-DOTATOC PET/CT of a 72-year-old patient with lung NEC. 
The images show only minimal SMS-R expression in the primary tumor, 
which is located in the right lung. Additionally, a cerebral metastasis was 
detected, supporting the indication for percutaneous radiation therapy. 
(a) Maximum intensity projection, (b) PET axial section, (c) CT axial sec-




















   
   
   
   
   
   
   
   
   
   
   

























progressing. The review included 9 (7%) patients with lung 
carcinoids, 4 with TCs, and 5 with ACs. The median time to 
progression after PRRT with 177Lu-DOTATATE was 31 
months in this small subgroup. In 5 patients partial remission 
(PR) was achieved, 1 patient demonstrated minor remission, 
and 2 patients had SD [27]. However, there is no data yet from 
randomized controlled studies and prospective evaluation of 
tumor response rates and survival. Furthermore, there are no 
trials restricted to patients with lung NETs, and only few 
 subgroup analyses exist with small numbers of lung NET 
 patients from previous studies.
Chemotherapy
Only sparse data exists also concerning the chemotherapy 
of NETs of the lung. Therefore, no standard treatment regi-
men has been established yet [28]. Streptozotocine (STZ)-
based regimens have no significant value in SCLC treatment 
[29]. Furthermore, in advanced NETs of the lung, the results 
of STZ-based therapies in terms of response and stabilization 
rates are rather discouraging and suggest that NETs of the 
lung include a high proportion of STZ-resistant tumors [30]. 
In a non-controlled trial, 36 patients with metastatic NETs 
were treated with a combination of cisplatin and etoposide 
(PE). In 18 of these patients, the tumor originated from the 
lung or from the thymus, of which 5 were atypical. In this 
 subgroup of thoracic NETs, 56% responded to therapy with a 
medium duration of 9 months, one-third achieved SD [31]. 
These results have made the PE regimen a valuable compara-
tor in this patient group. However, there is no consensus yet 
on the question of whether the use of cisplatin and etoposide 
should be limited to SCLC treatment or extended to other 
 advanced NETs of the lung.
At least in patients with LCNEC, cisplatin-containing 
 combinations have been shown to be of particular relevance 
[32]. In a retrospective series of 20 patients with LCNEC 
treated with different cisplatin-based regimens, 1 patient 
showed complete response (CR) and 9 showed PR, yielding 
an objective response rate of 50%. These results suggest that 
the response rate of LCNECs to cisplatin-based chemother-
apy is comparable to that of SCLCs [33] and they should be 
treated alike.
Temozolomide-based chemotherapies have been revealed 
to be effective in patients with pancreatic NETs and might 
serve as an alternative treatment option in lung NETs. 
A phase II study included 36 patients with advanced well- 
differentiated NETs. 13 of them were bronchial NETs, i.e. 
10 TCs and 3 ACs. All patients received oral temozolomide for 
5 consecutive days within 28-day cycles after failure of several 
other treatments. 4 (31%) patients achieved a PR, whereas 
4 others (31%) showed SD [34]. Other compounds in the 
 chemotherapy of lung NETs include, e.g., capecitabine and/or 
oxaliplatin.
It should be noted that, beyond the intraluminal part of the 
tumor which is visible in bronchoscopy, there is sometimes a 
much bigger extraluminal tumor mass which can be detected 
using EBUS. The minimally invasive approach is recom-
mended only for patients who are unfit for surgery. In these 
cases, photodynamic therapy might be a good option [24]. 
 Endoscopic resection should be followed up by control endos-
copies at frequent intervals.
In patients with neuroendocrine tumorlets (DIPNECH), 1 
or 2 of the lesions should be resected via thoracoscopy in 
order to prove the diagnosis histologically. All lesions should 
be followed up at regular intervals. Since this is rather a slowly 
growing tumor disease, 6-month intervals by conventional 
 imaging seem to be appropriate. Tumor resections may be 
considered in the case of radiological progression of single 
 lesions, unless a systemic treatment is required.
Biotherapy
The symptoms of hormonal excess in functionally active 
NETs of the lung can be similar to those in GEP NETs. Carci-
noid syndrome (see above) can be treated effectively with 
SSAs such as octreotide or lanreotide. In cases of insufficient 
response to monotherapy, the SSAs may be combined with 
 interferon alpha.
Due to only sparse data from clinical studies concerning 
the antitumor effects of SSAs in lung NETs, it remains unclear 
whether there is a comparable antiproliferative effect to that 
shown for octreotide LAR in patients with advanced well- 
differentiated midgut NETs [25]. The same holds true for 
other biotherapies such as interferon. The new SSA SOM230 
(pasireotide) is an SSTR multiligand. Preliminary results from 
phase II clinical studies show its efficacy in patients with intes-
tinal NETs and octreotide-refractory carcinoid syndrome [26].
Peptide Receptor Radionuclide Therapy
Radiolabeled SSAs are used in PRRT for the treatment 
of SSTR-positive NETs. Results from non-controlled, 
mostly monocentric clinical trials are encouraging. Using 
third-generation SSTR-based radiopharmaceuticals, namely 
177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE; DOTA = 
1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid), 
the adverse effects of PRRT are mostly mild. Serious adverse 
effects like myelodysplastic syndrome/acute myelogenous 
l eukemia or chronic renal failure are very rare. However, 
 possible long-term effects on renal functions need to be taken 
into account when using 90Y-labeled peptides. According to a 
systematic review, with 177Lu-DOTATATE, tumor regression 
of 50% or more was demonstrated in 28% of NET patients 
and of 25–50% in 19% of all patients. Stable disease (SD) was 
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Within the single-arm open-label study RAMSETE 
(RAD001 in Advanced and Metastatic Silent neuro-Endo-
crine Tumors in Europe), patients received a monotherapy 
with everolimus. 73 Patients with non-functional, non-pancre-
atic NETs of different origins, including the lung, were re-
cruited. 55 (75%) of the patients discontinued, 23 due to dis-
ease progression, another 23 due to adverse events. According 
to the centralized review, 55% of the patients reached SD 
after prior disease progression and the median PFS was 185 
days [39].
Future Perspectives
Currently, patients with advanced NETs of GI or lung 
 origin and without a history of carcinoid syndrome are 
being recruited for the multicenter study RADIANT-4 
(CRAD001T2302). In combination with best supportive care, 
everolimus will be compared to placebo in a randomized 
 double-blind setting. The study is planned to enroll 279 pa-
tients from over 120 sites worldwide. Treatment-naive patients 
will be included as well as patients with disease progression 
on or after the last treatment [40].
The European multicenter 3-arm trial CSOM230DIC03 
 including everolimus will start to recruit patients with lung 
NETs. The trial will compare the effectiveness and tolerability 
of everolimus or the SSA SOM230 (see above), alone or in 
combination, in about 80 patients with advanced TCs and ACs 
of the lung and thymus [41]. Using the typical platinum- 
doublet backbone as a standard approach, the German study 
CRAD001KDE37 is currently investigating the effectiveness 
and tolerability of the combination of everolimus, paclitaxel, 
and carboplatin in approximately 85 patients with advanced 
LCNEC [42]. These two trials are coordinated for Germany 
by Wilfried Eberhardt (CSOM230DIC03) and Michael 
Thomas (CRAD001KDE37).
Another agent that might be of interest for the therapy of 
patients with lung NETs is the angiogenesis inhibitor bevaci-
zumab. A phase II study compared bevacizumab to polyethyl-
ene glycol (PEG) interferon alpha-2b, both in combination 
with octreotide. The trial included 44 patients with advanced 
NETs of different origins, 4 (2.3%) of them originating from 
the lung. Upon bevacizumab treatment, 4 patients (18%) 
demonstrated a PR, 17 patients (77%) SD, and 1 patient (5%) 
PD. Upon treatment with PEG interferon, 15 patients (68%) 
achieved SD and 6 patients (27%) developed PD. The PFS 
rates after 18 weeks of monotherapy were 95% with bevaci-
zumab versus 68% in the PEG interferon arm [43].
Summary and Conclusions
NETs of the bronchopulmonary system are a rare entitity 
of highly to moderately differentiated tumors, which can be 
Molecularly Targeted Agents
Several new compounds are candidates for molecularly tar-
geted therapy in NETs. However, only few agents have been 
evaluated in controlled clinical trials, so far. Nonetheless there 
are results from 2 phase III clinical trials with the tyrosine 
 kinase inhibitor sunitinib and the mammalian target of ra-
pamycin (mTOR) inhibitor everolimus (RAD001). These 
 trials exclusively included pancreatic NET patients. With both 
agents, an increase of the median progression-free survival 
(PFS) by 6 months compared to placebo could be demon-
strated, whereas the objective response rates according to 
 RECIST were low: 9% for sunitinib and 5% for everolimus. 
Generally, these compounds were well tolerated and adverse 
events declined in most cases within the first 3 months of 
treatment [35, 36].
Everolimus and sunitinib have been approved recently for 
the treatment of advanced well-differentiated NETs of pan-
creatic origin with tumor progression; there are, however, no 
data on the efficacy of sunitinib in lung NETs.
In the phase III trial RADIANT-2 (RAD001 In Advanced 
Neuroendocrine Tumors-2), everolimus was compared with 
placebo, both in combination with octreotide, including 
429 patients with advanced, well- to intermediately differenti-
ated NETs of different origin. Primary endpoint of the trial 
was the median PFS undergoing a centralized radiological 
 review, which was 16.4 months with everolimus versus 11.3 
months with placebo for the overall cohort of patients. 
 According to that, everolimus was associated with a 23% re-
duction in risk of progression (hazard ratio (HR) 0.77; 95% 
confidence interval (CI) 0.59–1.00; p = 0.026), but the log rank 
test one-sided p-value did not meet the pre-specified signifi-
cance level of p = 0.0246. However, the median PFS by inves-
tigator review was 12.0 and 8.6 months for everolimus and 
placebo, respectively, and thus consistent with the central 
analysis. From this point of view, everolimus was associated 
with a clinically significant reduction in risk of progression by 
22% (HR 0.78; 95% CI 0.62–0.98; p = 0.018) [37]. From this 
study, a subgroup of 44 patients with lung carcinoids was 
looked at in an exploratory PFS analysis. Although this is a 
small patient cohort, it is the largest number of patients with 
lung NETs prospectively evaluated in a clinical trial. 75% of 
these patients had received everolimus, 25% placebo. Within 
the lung carcinoid subgroup, the PFS analysis showed a non-
significant trend in favor of everolimus versus placebo. The 
median PFS was 13.6 months in the everolimus subgroup and 
5.6 months in the placebo subgroup [38]. Due to diverging 
characteristics of the two patient groups, these results must be 
interpreted with caution until they can be verified in further 
prospective clinical studies with larger numbers of patients. 
However, this could be an important step forward in the man-
agement of this tumor. The RADIANT-4 study (see below) 
will further evaluate the role of everolimus in lung (and GI) 




















   
   
   
   
   
   
   
   
   
   
   

























based on studies with small numbers of lung NET patients, 
and further research in randomized controlled studies is nec-
essary to draw reliable conclusions.
The introduction of new therapies in the treatment of 
NETs can be expected for the future. However, there is still a 
great need to generate meaningful clinical data for patients 
with lung NETs, which are even rarer than NETs in general. 
For this reason, the implementation of specific lung NET reg-
istries and cross-linking international research activities are 
critical for the future of this field. Since NETs of the lung and 
GEP NETs share some features with respect to biological 
b ehavior and clinical characteristics, it may be reasonable to 
establish common interdisciplinary tumor boards and regis-
tries as well. However, no consensus could be achieved con-
cerning this question, and there may also be certain benefits in 
NET treatment associated with tumor boards specialized in 
thoracic oncology. Currently, LUNGEN NET, which is a Ger-
man prospective registry for NETs of the bronchopulmonary 
system, is being implemented under the chairmanship of 
Christian Grohé and Dieter Hörsch.
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classified by their histology, proliferative activity, TNM staging, 
endocrinological activity and hereditary background. Well- 
differentiated bronchopulmonary NETs comprise approxi-
mately 2% of all lung tumors. Prognosis in TCs is mostly good. 
In ACs, histopathology and prognosis are intermediate be-
tween TCs on the one hand and LCNEC or SCLC on the 
other hand. The overall 5-year survival rate in bronchopulmo-
nary carcinoids can be estimated at 90%. A huge proportion of 
the bronchopulmonary carcinoids are asymptomatic at  initial 
diagnosis. In other cases, they appear with cough,  hemoptysis, 
and bronchopulmonary infections. Bronchoscopical explora-
tion and adequate cell sampling through biopsy are crucial for 
the correct diagnosis of the tumor. For the pathohistological 
differentiation between TC and AC, the mitotic count and the 
presence of necrosis are the most important  parameters. Im-
munohistochemistry can be useful for the diagnosis of NETs 
as well as for the detection of a neuroendocrine component, 
for example in squamous-cell carcinomas or  adenocarcinomas. 
Virtually all TCs and ACs are positive for CgA and synapto-
physin. Contrarily, NSE, which is the commonly used marker 
for SCLC and LCLC, has a very low specificity and is there-
fore not suitable for routine pathology in NETs. Serum mark-
ers such as CgA and NSE can be valuable tools for follow-up 
examination, but not for tumor screening. Measurement of 
5-HIAA is of limited value in most lung NETs. New imaging 
techniques, especially functional imaging with radiolabeled 
SSA, significantly improved the diagnosis of NETs.
The only curative treatment for lung NETs is their com-
plete resection. The use of ablation methods should be consid-
ered in tumors that cannot be completely resected via surgery. 
Carcinoid syndrome can be treated effectively with SSAs. 
However, concerning NETs of the lung, it remains unclear 
whether there is an additional effect of biotherapy in terms of 
tumor control. Results from non-controlled trials with PRRT 
are promising and need further evaluation in randomized con-
trolled studies. Due to sparse clinical data, there is so far no 
standard chemotherapy regimen for NENs of the lung. A high 
proportion of NETs seems to be STZ resistant. Promising 
candidates for chemotherapy components in the field of bron-
chopulmonary NETs are, e.g., cisplatin, etoposide, temozolo-
mide, capecitabine, and oxaliplatin. The new molecularly tar-
geted compounds everolimus and sunitinib have been recently 
approved for the treatment of advanced, progressing well-dif-
ferentiated pancreatic NETs. First results with everolimus in 
the treatment of lung NETs are promising. However, they are 
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